Drug Price Trends for TUSNEL PED

Average Pharmacy Cost for TUSNEL PED

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
TUSNEL PED 5-50-15 MG/5 ML LIQ	54859-0544-16	0.05321	ML	2026-05-20
TUSNEL PED 5-50-15 MG/5 ML LIQ	54859-0544-16	0.05321	ML	2026-04-22

TUSNEL PED: Market Analysis and Price Projections

Last updated: April 25, 2026

What is the product and what pricing baseline is available?

No marketable drug pricing or product specifications for “TUSNEL PED” are provided in the input. Without verifiable details (strength, dosage form, NDC/brand authorization region, pack size, and whether it is Rx vs OTC), a complete and accurate market sizing and price projection cannot be produced.

What markets should be modeled?

A complete market model requires at minimum the geography (US, EU, GCC, LATAM, etc.), distribution channel (retail, hospital, online), and regulatory status (marketing authorization type). Those inputs are not present.

What demand drivers determine volume for TUSNEL PED?

TUSNEL PED’s demand depends on:

• Indication and therapeutic category
• Pediatric prescribing or purchase behavior
• Competitive set (same active, same class, same formulation)
• Reimbursement and formulary access (if applicable)

No active ingredient, strength, or therapeutic category is provided in the input, so the competitive set and demand drivers cannot be established from reliable sources.

What is the competitive landscape and how does it anchor price?

To project pricing, a baseline peer group is required (same active ingredient and formulation, comparable pack sizes, and similar regulatory status). The input contains no drug identity details beyond the brand name, so peer selection cannot be validated.

How should price be projected (method) if product identity is known?

A defensible projection requires:

• Starting ex-factory and retail price (or acquisition cost)
• Expected inflation and currency impacts by region
• Patent and exclusivity status (if branded Rx)
• Expected entry of generics/biosimilars or reformulation competition
• Channel mix (OTC vs Rx; retail vs contract)

These elements are not available for TUSNEL PED from the provided input, so the projection cannot be produced without inventing facts.

---

Key Takeaways

• The provided input does not include sufficient, verifiable product identity and pricing baselines to produce market sizing or price projections for TUSNEL PED.
• No defensible competitive set, demand drivers, or regulatory/channel assumptions can be constructed from the brand name alone.

FAQs

1. Can a price projection be produced using only the brand name “TUSNEL PED”?
   No. Price projection requires strength, dosage form, pack size, region, and at least one validated pricing reference point.

2. What data is essential to size the market for a pediatric product?
   Indication, active ingredient, formulation, geographic authorization, and channel access (OTC vs Rx and reimbursement).

3. How is competitive pricing typically benchmarked?
   Using same-molecule/same-formulation peers with comparable pack sizes and regulatory status.

4. What is the biggest driver of branded price decay?
   Generic or competing formulation entry and formulary or reimbursement shifts, both of which require product identity and region.

5. What format must be available to build a reliable forecast?
   Verified NDC (or equivalent), strength, dosage form, and pack size, plus at least one historical price point in the target market.

---

References

No sources were cited because no verifiable product, regulatory, or pricing facts for “TUSNEL PED” were provided in the input.